Skip to content

Depression: all studies

Page 468 of 1,035: studies 4,671 to 4,680 of 10,348, newest first. Back to the depression overview

Research

Stroboscopic Light Stimulation in Adults Reporting Depressive Symptoms: Safety, Tolerability, Feasibility, and Active-Comparator Development in a Staged Early-Phase Study

medRxiv Preprint Server June 17, 2026 Danny Nacker, Luise Kalus, Anil K. Seth et al. preprint

Stroboscopic light stimulation (SLS) is a candidate non-pharmacological intervention that induces transient visual and affective experiences, with potential application in depression. Before efficacy testing, clinical development requires safety, tolerability and feasibility data. We report a staged, single-site programme in adults reporting depressive symptoms. Work Package (WP) 1 tested 11...

Short- and Long-Acting Psychedelics: Structure-Activity Relationships, Pharmacology, and Implications for Neuropsychiatric Therapeutics.

ACS Chemical Neuroscience June 17, 2026 Anoushka Bhat, Elmira Zolali, Mahfuz A Sakib et al.

Psychedelics have re-emerged as promising therapeutics for neuropsychiatric disorders, including depression, anxiety, post-traumatic stress disorder, and substance use disorders. While their beneficial effects are largely attributed to serotonin 2A (5-HT2A) receptor activation, psychedelics exhibit substantial diversity in chemical structure, receptor binding kinetics, metabolism, and duration...

Anxiety-related platform in zebrafish (Danio rerio) larvae: An integrated analysis of behavioural and molecular assay in drug screening research

Biomedicine & Pharmacotherapy June 17, 2026 Małgorzata Potoczna, Natalia Kasica, Małgorzata Chmielewska-Krzesińska et al.

Zebrafish larvae are increasingly used in behavioural pharmacology because of their translational relevance and suitability for anxiety- and stress-related studies. However, it remains unclear whether commonly used behavioural assays and molecular stress markers provide convergent evidence of anxiolytic-like drug activity. This study therefore aimed not to validate a single predictive screening...

DOI: 10.1016/j.biopha.2026.119680 (opens in new tab) Zebrafish Drug discovery Screening techniques Phenotypic screening +4

Burnout Symptom Outcomes During At-Home Ketamine-Assisted Therapy: A Real-World Retrospective Analysis of 395 Adults

Research Square June 16, 2026 Jack Swain, Davis Carter, Leonardo Vando et al. preprint

Abstract Background Occupational burnout, recognized in ICD-11 as an occupational phenomenon, is a syndrome of chronic workplace stress comprising emotional exhaustion, cynicism (the analogue of the depersonalization dimension on the MBI-Human Services Survey form), and reduced professional efficacy on the Maslach Burnout Inventory-General Survey (MBI-GS). Burnout is common among US working...

Psilocybin-Assisted Therapy for Common Mental Health Disorders and their Comorbid Presentations: A Scoping Review

June 15, 2026 Nandita Jowaheer preprint

This project is a scoping review examining the current evidence base for psilocybin-assisted therapy across depression, anxiety disorders, substance use disorders, and their comorbid presentations. The review aims to map the scope of existing research, summarise reported therapeutic outcomes, and evaluate the methodological quality of the evidence base. The full study rationale, objectives,...

Auditory Hallucinations in Occupational Contexts: Clinical and Organizational Implications

Bulletin of Integrative Psychiatry June 15, 2026 Vlad Teodor Iacob, Călin Scripcaru, Anton Knieling et al.

Auditory hallucinations (AH) represent sensory perceptions occurring in the absence of an external acoustic stimulus and are traditionally associated with psychotic disorders; however, growing evidence suggests that these phenomena may arise across a broader clinical and nonclinical spectrum. The present paper aims to examine auditory hallucinations through an integrated clinical,...

DOI: 10.36219/bpi.2026.2.04 (opens in new tab) Distress Stimulus psychology Cognition Psychosis +7

Music Playlist Use in Clinical Trials of Psychedelic Assisted Psychotherapy: A Systematic Review

Journal of Clinical Psychology June 15, 2026 Lucas Cruz, Fernando R. Beserra, Julia M.k. Freind et al.

Recent studies have shown promising results for psychedelics in the treatment of psychiatric disorders. Both in clinical and recreational settings, contextual elements, such as music, can influence the experience of users and may be linked to positive outcomes. This systematic review identifies how music is being selected and used in psychedelisc-assisted psychotherapy (PAP). The search adopted...

DOI: 10.1002/jclp.70167 (opens in new tab) Psilocybin Music therapy Clinical trial Scopus +8

Cetamina na depressão resistente ao tratamento: evidências, limitações e perspectivas clínicas

Revista Sociedade Científica June 13, 2026 Henrique Cardoso de Freitas, Andra Cristina Catelan-Mainardes

Cerca de 30% dos pacientes com transtorno depressivo maior não respondem a nenhum dos antidepressivos. Caracterizando a depressão resistente ao tratamento (DRT). Esta revisão narrativa teve como objetivo analisar criticamente as evidências sobre o uso da cetamina e da escetamina no tratamento da DRT, incluindo eficácia, mecanismos de ação, perfil de segurança e barreiras de acesso. Foram...

DOI: 10.61411/rsc2026137419 (opens in new tab) Context archaeology Fight-or-flight response Intensive care unit Randomized controlled trial +2

Ketamine and Evolving Neuroplasticity.

Clinical drug investigation June 13, 2026 Angel Prabakar

Ketamine has revolutionized the treatment of mood disorders by offering rapid antidepressant effects, particularly in individuals with treatment-resistant depression. Unlike traditional monoaminergic antidepressants, ketamine acts primarily through antagonism of the N-methyl-D-aspartate (NMDA) receptor, initiating a cascade of glutamatergic signaling that promotes synaptic plasticity,...

Balancing safety and access in Oregon’s psilocybin services

International Journal of Drug Policy June 13, 2026 Katherine Cheung, Caleigh Propes, David B. Yaden

As jurisdictions across the U.S. consider enacting policies that facilitate access to psychedelics, they must determine how the desire to expand access to these substances should be weighed against the need to adequately protect safety. Oregon's psilocybin services program offers an important early case study of this balance in practice. Under the Psilocybin Services Act, adults over 21 are...

DOI: 10.1016/j.drugpo.2026.105384 (opens in new tab) Psilocybin Hallucinogen Medline Poison control +3